luminal side of intestinal epithelial cells (4, 6, 7) . In preclinical models, this interaction elevates intracellular and extracellular levels of cyclic GMP (cGMP), inducing fluid secretion and accelerating intestinal transit (4, 6, 8) . Preclinical models also show that a single dose of linaclotide can induce acute analgesia (4, 9) . This effect is proposed to be mediated by the downstream effector of GC-C, cGMP, released basolaterally from colonic epithelial cells via cGMP efflux pumps, which inhibits colonic nociceptors by a mechanism that is currently unclear but being actively investigated (4).
Introduction
Irritable bowel syndrome (IBS) is a prevalent functional gastrointestinal disorder affecting approximately 11% of the global population (1) . IBS places a significant financial burden on society and negatively affects the quality of life of those affected (1, 2) . IBS is characterized by chronic abdominal pain or discomfort associated with altered bowel habits and is subclassified as IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), and alternating/ mixed IBS (A/M-IBS) (1, 2) . Abdominal pain is a key clinical feature of IBS and, paradoxically, is the most difficult symptom to treat (1, 2) . Opioids are frequently used for pain management, yet their chronic use causes tolerance, dependence, and reduced analgesic efficacy, resulting in the current "opioid epidemic" (3) . Importantly, chronic opioid use causes severe constipation, making opioid use in patients who already have constipation, such as the 33% of IBS patients who have IBS-C, problematic. Accordingly, opioids are not efficacious in treating visceral pain, and new analgesic treatments for visceral pain syndromes such as IBS are urgently required.
We have shown that linaclotide, an FDA-approved, synthetic, 14-amino acid peptide agonist of guanylate cyclase-C (GC-C), improves abdominal pain and bowel symptoms in IBS-C patients (4, 5) . Linaclotide is minimally absorbed and acts locally within the gastrointestinal tract on GC-C expressed on the Irritable bowel syndrome (IBS) patients suffer from chronic abdominal pain and extraintestinal comorbidities, including overactive bladder (OAB) and interstitial cystitis/painful bladder syndrome (IC-PBS). Mechanistic understanding of the cause and time course of these comorbid symptoms is lacking, as are clinical treatments. Here, we report that colitis triggers hypersensitivity of colonic afferents, neuroplasticity of spinal cord circuits, and chronic abdominal pain, which persists after inflammation. Subsequently, and in the absence of bladder pathology, colonic hypersensitivity induces persistent hypersensitivity of bladder afferent pathways, resulting in bladder-voiding dysfunction, indicative of OAB/IC-PBS. Daily administration of linaclotide, a guanylate cyclase-C (GC-C) agonist that is restricted to and acts within the gastrointestinal tract, reverses colonic afferent hypersensitivity, reverses neuroplasticity-induced alterations in spinal circuitry, and alleviates chronic abdominal pain in mice. Intriguingly, daily linaclotide administration also reverses persistent bladder afferent hypersensitivity to mechanical and chemical stimuli and restores normal bladder voiding. Linaclotide itself does not inhibit bladder afferents, rather normalization of bladder function by daily linaclotide treatment occurs via indirect inhibition of bladder afferents via reduced nociceptive signaling from the colon. These data support the concepts that crossorgan sensitization underlies the development and maintenance of visceral comorbidities, while pharmaceutical treatments that inhibit colonic afferents may also improve urological symptoms through common sensory pathways.
available online with this article; https://doi.org/10.1172/jci.insight.121841DS1). While colonic inflammation spontaneously healed over a 7-day period (Supplemental Figure 1 ), these mice subsequently developed chronic colonic afferent mechanical hypersensitivity in the postinflammatory state (4, (18) (19) (20) (21) . First, we showed that CVH mice administered vehicle (saline oral gavage, once daily for 2 weeks, from 14 to 28 days after intracolonic TNBS administration) displayed allodynia and hyperalgesia in response to colorectal distension (CRD) relative to control mice administered vehicle ( Figure 1A ). This indicates that the process of chronic oral gavaging mice per se does not interfere with the development of CVH. Next, we showed that control mice administered either chronic daily linaclotide or vehicle displayed similar pain responses to CRD across a range of pressures ( Figure 1B) . In contrast, CVH mice chronically administered daily linaclotide showed significantly reduced pain responses to CRD compared with CVH mice administered vehicle ( Figure 1C ). These changes were not associated with alterations in colonic compliance (Supplemental Figure 2 ), suggesting that they are mediated at the level of the primary afferent, rather than secondary to changes in the ability of the colon to accommodate an increase in volume. Overall, CVH mice administered daily linaclotide exhibited similar pain responses to those of control animals (Figure 1 , B-D), suggesting that chronic linaclotide treatment reverses the allodynia and hyperalgesia normally apparent in CVH states.
Colitis induces chronic hypersensitivity of colonic nociceptors, which is reversed by chronic daily linaclotide treatment. To determine if the linaclotide-induced reversal of allodynia and hyperalgesia in CVH states is due to long-term inhibition of peripheral sensory drive from the colon we performed ex vivo recordings of colonic nociceptors from mice administered either chronic linaclotide or vehicle. Colonic nociceptors from CVH mice displayed increased responsiveness to mechanical stimuli (4, (18) (19) (20) (21) . We found that control mice administered daily linaclotide displayed modest reductions in colonic afferent responses to mechanical stimuli relative to those of vehicle-treated control mice ( Figure 1 , E and F). In contrast, colonic nociceptors from CVH mice administered daily linaclotide for 2 weeks showed pronounced decreases in mechanical responsiveness ( Figure 1 , G and H) and normalized activation thresholds (Supplemental Figure 3 ) relative to those of vehicle-treated CVH mice. These findings suggest that chronic linaclotide treatment reverses the chronic mechanical hypersensitivity of colonic nociceptors normally observed in CVH states.
Colitis induces neuroplasticity within the dorsal horn of the spinal cord, which is reversed by chronic daily linaclotide treatment. We next assessed if the linaclotide-induced suppression in peripheral drive from the colon resulted in corresponding changes in nociceptive signaling within the dorsal horn of the spinal cord. To do this, we identified activated dorsal horn neurons in response to noxious (80 mmHg) CRD by phosphorylated MAP kinase ERK 1/2 immunoreactivity (pERK-IR). CVH mice treated with vehicle displayed significantly more activated dorsal horn neurons in response to noxious CRD compared with vehicle-treated CVH mice ( Figure 2A ). In control mice, daily linaclotide treatment did not alter the number of activated dorsal horn neurons in response to noxious CRD relative to that in vehicle-treated control mice ( Figure 2 , A and B). In contrast, daily linaclotide treatment in CVH mice resulted in significantly fewer pERK-IR dorsal horn neurons after noxious CRD compared with vehicle-treated CVH mice ( Figure 2 , A and C). This decrease was particularly apparent within lamina I, II, and V of the dorsal horn, with the number of activated neurons similar to that in control conditions ( Figure 2 ). In order to determine if different populations of pERK-IR neurons were activated in CVH states, we colabeled for calbindin (excitatory neurons, ref. 22) or GABA (inhibitory interneurons, ref. 22; Supplemental Figure 4) . While the number of pERK-IR neurons expressing calbindin did not change between conditions and treatments (Supplemental Figure 4 , A and B), we observed a significant increase in the percentage of pERK-IR dorsal horn neurons expressing GABA (Supplemental Figure 4 , C and D). This effect was partially reversed in CVH mice treated with linaclotide.
We have previously shown that CVH mice display sprouting within the spinal cord of the central terminals of colon-innervating afferents, particularly within lamina I but also deeper laminae (23) . We therefore sought to determine if the linaclotide-induced decrease in peripheral sensory drive from the colon, plus the reduced activation of dorsal horn neurons in response to noxious CRD, would alter sprouting of colonic afferent central terminals in CVH states. We found that, relative to control animals, CVH vehicle-treated mice displayed an increased optical density ( Figure 3A ) and area covered by colonic afferent central terminals in the dorsal horn (laminae I and II) ( Figure 3B ), as identified by fluorescent retrograde labeling of colon-innervating neurons using CTB-555 ( Figure 3C and Supplemental Figure 5 ). CVH mice treated daily with linaclotide showed a reduced density and distribution of colonic afferent central terminals, suggesting sprouting of these terminals within the spinal cord was not as extensive as that normally observed in CVH mice ( Figure 3 and Supplemental Figure 5 ). Collectively, these findings suggest that daily linaclotide treatment reverses CVH-associated neuroplasticity in colonic afferent pathways.
Exogenous cGMP inhibits colon-innervating DRG neurons via a membrane receptor target that is accessed extracellularly. Previous studies suggest that the GC-C agonist linaclotide does not directly inhibit nociceptors, rather the downstream effector of GC-C, cGMP released basolaterally from colonic epithelial cells, inhibits colonic nociceptors (4). However, this mechanism and the manner in which cGMP exerts these inhibitory actions remain to be fully elucidated. Using whole-cell patch-clamp electrophysiology of colon-innervating DRG neurons, we confirmed that linaclotide does not affect the excitability of these neurons ( Figure 4 , A and B). Colon-innervating DRG neurons from CVH mice displayed pronounced neuronal hyperexcitability relative to that of control counterparts ( Figure 4C ). In contrast to linaclotide, exogenous application of cGMP inhibited a large population of colon-innervating DRG neurons, particularly in CVH states (Figure 4 , D-F). In CVH DRG neurons, cGMP caused a dose-dependent inhibition of neuronal excitability, significantly increasing the amount of injected current required to fire an action potential (Figure 4 , F and G). Importantly, cGMP was still able to inhibit colonic nociceptors from mice lacking GC-C (gucy2c -/-; Supplemental Figure 6 ).
Having confirmed that cGMP, rather than linaclotide, inhibits colonic nociceptors, the question remained as to the underlying mechanism. Although active mechanisms for transport of cGMP out of cells have been described, passive diffusion of cGMP across cell membrane is poor, and cGMP is not actively transported back into cells (24) . We therefore hypothesized that the effects of cGMP on colonic nociceptors are via a membrane target accessible extracellularly. To investigate this, we utilized fluorescence resonance energy transfer-based (FRET-based) analysis of genetically encoded fluorescent biosensors for cGMP. DRG neurons were isolated from R26-CAG-mcGi500(L1) mouse embryos, which express the membrane-targeted version of cGi500, a cGMP indicator with an EC 50 of 500 nmol/l that displays fast binding kinetics and exquisite selectivity for cGMP (25) (26) (27) . Application of C-type natriuretic peptide (CNP; used as a positive control, as it results in the intracellular production of cGMP) to R26-CAG-mcGi500 DRG neurons increased the CFP/YFP emission ratio in the cell soma ( Figure 4 Overall, these findings confirm that cGMP inhibits colonic nociceptors via a membrane target that is accessed extracellularly.
Human DRG neurons are also inhibited by exogenous cGMP. To further investigate the translatability of our findings, we tested the ability of exogenously applied cGMP to inhibit human DRG neurons from organ donors. Using whole-cell patch-clamp electrophysiology, we found that application of exogenous cGMP caused a dose-dependent decrease in the number of action potentials fired by human DRG neurons ( Figure 5 , A and B). In order to simulate a pathological state, we incubated a subset of the DRG neuronal cultures with an inflammatory soup (histamine: 10 M, PGE-II: 10 μM, serotonin: 10 μM, bradykinin: 10 μM) for 2 hours. Human DRG neurons from these cultures displayed pronounced hyperexcitability ( Figure 5C ), with application of exogenous cGMP causing a dose-dependent decrease in the number of action potentials fired ( Figure 5 , D and E). Overall, more human DRG neurons from the inflammatory soup cultures were inhibited by cGMP compared with human DRG neurons from the normal cultures ( Figure 5F ).
Mice with colitis-induced CVH display altered bladder-voiding patterns, an effect that is reversed by chronic daily linaclotide treatment. We hypothesized that mice with CVH following spontaneous recovery from TNBS-induced colitis also exhibit altered bladder function, indicating the development of an OAB/IC-PBS phenotype. To investigate this, we examined mouse bladder-voiding patterns before and at 7, 14, 21, and 28 days following intracolonic TNBS treatment ( Figure 6 ). Filter paper samples from the cages of control mice showed a distinctly organized pattern of voiding throughout the time course of the experiment, from day 1 through day 28 ( Figure 6 , A-E). In contrast, CVH mice began to develop a disrupted, scattered voiding pattern by day 14 after intracolonic TNBS, which was maintained and exacerbated by day 28 (Figure 6 , B-J). At day 28, these changes were characterized by an increase in the number of small-and medium-sized urine spots ( Figure 6 , I and J) as well as an altered distribution throughout the cage, indicative of the OAB/ IC-PBS symptoms of urgency and frequency. In CVH mice due to receive either vehicle or linaclotide treatment, we saw a similar pattern of voiding dysfunction at day 14 ( Figure 6 , C, D, G, and H). However, following initiation of chronic oral linaclotide administration (started on day 14 after intracolonic TNBS), CVH-induced changes in voiding patterns were attenuated, normalizing at day 28 both the distribution and the number of small-and medium-sized urine spots relative to vehicle-treated CVH mice ( Figure 6 , C-J). Notably, colitis did not induce local inflammation or changes in bladder histology at any time point tested following TNBS-induced colitis (Supplemental Figure 1) , indicating that the changes we see in bladder-voiding patterns are not a direct result of local bladder inflammation.
CVH mice show enhanced bladder afferent responses to distension, which are reversed by chronic daily linaclotide treatment. To understand the mechanisms underlying the changes in bladder-voiding parameters observed in CVH mice, we next sought to examine bladder afferent responses to bladder distension. Multiunit ex vivo pelvic afferent recordings from control mice showed that, as pressure within the bladder increased, there was a corresponding increase in action potential discharge ( Figure 7 , A and B). However, bladder afferents from CVH mice displayed a significantly enhanced response to distension compared with control mice, particularly at 10-30 mmHg of bladder distension, pressures that are likely to trigger bladder voiding in states of OAB/IC-PBS ( Figure 7, A and B ). This suggests that the aberrant bladder-voiding patterns we observed in the current study could be mediated by changes in bladder afferent mechanosensitivity. Furthermore, by examining the pressure-volume relationship in the bladder during distension, we identified that there was no difference in muscle compliance (Supplemental Figure 7A ) or contractility (Supplemental Figure 8A ) between control and CVH mice. This suggests that the significant changes in bladder afferent mechanosensitivity in CVH mice are mediated at the level of the primary afferent, rather than secondary to changes in the ability of the bladder to accommodate an increase in volume. As we demonstrated that daily linaclotide is able to normalize bladder-voiding patterns and reduce colonic afferent sensitivity, we hypothesized that linaclotide may also be able to attenuate colitis-induced bladder hypersensitivity. Here, we show that CVH mice receiving daily linaclotide treatment had significantly reduced bladder afferent sensitivity to distension (0-30 mmHg) compared with vehicle-treated CVH mice ( Figure 7 , C and D). However, chronic linaclotide administration had no effect on bladder muscle compliance (Supplemental Figure  7B ) or bladder muscle contractility (Supplemental Figure 8B) , demonstrating that linaclotide's effect on reducing bladder afferent mechanosensitivity is independent of altered muscle compliance or contractility.
Daily linaclotide treatment prevents colitis-induced increases in bladder afferent chemosensitivity. To further investigate the effects of the CVH state on bladder afferent function, we examined the effect of purinergic (P2X 3 ), muscarinic, and transient receptor potential vanilloid 1 (TRPV1) receptor agonists on bladder afferent firing in control and CVH mice. Application of the individual agonists αβMe-ATP, carbachol, or capsaicin, respectively, caused significant bladder afferent activity from control mice (Figure 7 , E-G). However, afferent responses to these agonists were all significantly enhanced in bladder preparations from CVH mice (Figure 7 , E-G). In contrast, CVH mice treated daily with linaclotide showed significantly reduced bladder afferent responses to αβMe-ATP, carbachol, and capsaicin compared with CVH vehicle-treated mice (Figure 7 , H-J), normalizing afferent responses to these agonists.
Chronic daily linaclotide reduces the excitability of bladder-innervating DRG neurons from CVH mice. In this study, we have shown that CVH mice display enhanced mechanical and chemical sensitivity of the peripheral sensory endings innervating the bladder and that these effects are independent of altered smooth muscle properties or local inflammation. To determine if this hypersensitivity occurs directly at the neuronal level, we used whole-cell patch-clamp electrophysiology to measure neuronal excitability of bladder-innervating DRG neurons. Retrogradely traced bladder-innervating TL and LS DRG neurons from CVH mice displayed pronounced hyperexcitability compared with those from control mice (Figure 8 , A-C, and Supplemental Figure 9 ). Daily linaclotide treatment of CVH mice prevented CVH-induced hyperexcitability of bladder-innervating DRG neurons relative to vehicle-treated CVH mice (Figure 8 , A-C, and Supplemental Figure 9 ). Overall, these findings indicate that colitis-induced sensitization of colonic afferents is able to sensitize the cell bodies of bladder afferents and that chronic administration of linaclotide can prevent bladder afferent hypersensitivity in CVH states.
The effects of linaclotide are not mediated via direct actions within the bladder. Although linaclotide has a very low oral bioavailability and its receptor, GC-C, has been shown to be almost exclusively expressed in the mucosa of the gastrointestinal tract (4), we wanted to confirm that the effects seen in this study were not mediated by direct actions of linaclotide upon the bladder. Using in situ hybridization, we confirmed our previous findings and showed that GC-C is highly expressed in colonic epithelial cells ( Figure 8D) . In contrast to the colon, expression of GC-C was not evident within the bladder ( Figure  8D ). To further confirm our findings, we performed qPCR analysis of mRNA isolated from either primary colonic epithelial cells or bladder urothelial cells. These studies revealed that the colonic mucosa contained abundant GC-C mRNA expression, whereas GC-C mRNA expression was absent from the bladder mucosa ( Figure 8E ). In contrast, TRPV4, known to be expressed in bladder urothelial cells (28) , was abundantly expressed in bladder urothelium ( Figure 8E ). To functionally confirm a lack of action of linaclotide within the bladder, we used ex vivo bladder afferent recordings and infused linaclotide intravesically into the bladder during ramp distension (Figure 8 , F and G). Intravesical linaclotide had no effect on bladder mechanosensitivity to bladder distension in either control or CVH mice (Figure 8 , F and G). These findings support our hypothesis that the inhibitory effects of linaclotide treatment are not via a direct action within the bladder.
Crosstalk of colon and bladder afferents within the DRG and spinal cord. To investigate how bladder afferents become hypersensitive in CVH states and why CVH mice display bladder dysfunction, we performed concurrent retrograde tracing from the colon and bladder. This allowed us to determine if these organs are innervated by a substantial population of DRG neurons that have dichotomizing axons that project to both the colon and the bladder. We found that the vast majority (85%) of retrogradely traced DRG neurons in both control and CVH states contain only the tracer injected into the colon or the tracer injected into the bladder, with a small population of dual-labeled (15%) DRG neurons identified (Figure 9 , A-F). A direct comparison of the number of traced colon-only, bladder-only, or dual-traced neurons per ganglia showed no significant alterations in the populations between control and CVH states in either TL or LS DRG (Figure 9 , C and D). Furthermore, the percentage of colon-innervating neurons that also innervated the bladder (dual traced) did not alter between healthy and CVH mice (Figure 9 , E and F). However, within the DRG it is evident that individual bladder-or colon-or dual-innervating neurons are located within close proximity to one another ( Figure 9, A and B ), allowing potential "crosstalk" between these organs. In separate tracing studies, we investigated the central terminals of colon-innervating and bladder-innervating afferents by visualizing retrograde tracing from each organ. These data show that the colon-only and bladder-only central terminals lie in very close proximity to one another within the dorsal horn of the spinal cord, in particular within laminae I, the lateral spinal nucleus, and the lumbar dorsal column (Figure 9 , G-J). This close proximity provides potential opportunities for these central terminals to communicate with one another, allowing crosstalk between these organs onto shared spinal cord circuits. These findings may well explain why IBS patients have comorbidities, including abdominal pain and OAB/IC-PBS. and large-sized urine spots produced by control mice is similar for each time point throughout the 28-day study. (F) CVH mice display increased numbers of medium-sized urine spots at 28 days after intracolonic TNBS administration compared with baseline (day 1; prior to TNBS, **P < 0.01) or 7 days after TNBS (*P < 0.05, **P < 0.01). (G) CVH mice receiving vehicle treatment from 14-28 days after TNBS display increased numbers of medium-sized spots at day 21 (**P < 0.01) and day 28 after intracolonic TNBS (***P < 0.001). (H) CVH mice display more medium-sized urine spots at day 14 after TNBS (*P < 0.05), but, following chronic administration of linaclotide (from 14-28 days after intracolonic TNBS), the number of medium-sized urine spots is normalized. (I and J) Quantitative data at day 28 for all treatment groups showing a significant increase in (I) small-and (J) medium-sized spots in CVH (*P < 0.05, **P < 0.01) and CVH vehicle-treated (**P < 0.01) mice compared with control mice. Data represent mean ± SEM. P values are based on 1-way ANOVA followed by Bonferroni post hoc tests (E-J).
Discussion
IBS patients represent approximately 11% of the global population and suffer from chronic abdominal pain and altered gastrointestinal motility. The underlying pathogenesis of IBS is complex; however, there is a strong correlation between a prior exposure of the patient to gut infection and symptom occurrence (1, 2) . Such bouts of acute gastroenteritis can trigger IBS symptoms in patients that persist for at least 8 years after the initial infection (29) . IBS patients report visceral hypersensitivity but do not present with concurrent signs of gastrointestinal inflammation (1, 2, 10) . It is therefore suggested that patients develop neuroplasticity of visceral sensory pathways, which drives chronic abdominal pain in the absence of pathology in the postinflammatory state (1, 10) . Here, we demonstrate that, following resolution of colitis, in the postinflammatory state, colonic nociceptors display mechanical hypersensitivity and reduced activation thresholds, with the cell bodies of these afferents showing pronounced hyperexcitability. This increased nociceptive signal leads to increased activation of dorsal horn neurons within the spinal cord in response to noxious CRD. Notably, the neurochemistry of these activated dorsal horn neurons changes, with the recruitment of additional neuronal populations not seen in the healthy state. This may be a potential consequence of the increased density of the colonic afferent central terminals within dorsal horn lamina I and II. Correspondingly, CVH mice displayed allodynia and hyperalgesia in response to CRD, indicative of chronic abdominal pain ( Figure 9K ). As this neuroplasticity occurs at every level of the sensory pathways innervating the colon, these changes provide an underlying mechanistic basis for the presentation of chronic abdominal pain in the absence of pathology in patients with IBS.
Having demonstrated the underlying mechanistic processes by which chronic abdominal pain can occur, we determined whether it could be reversed. Here, we show that chronic daily treatment with linaclotide, an FDA-approved GC-C agonist for the treatment of IBS-C, (a) reversed mechanical hypersensitivity of colonic nociceptors, (b) reduced the number of activated dorsal horn neurons in response to CRD, (c) reduced the severity of colonic afferent central terminal sprouting, and, correspondingly, (d) normalized abdominal pain to CRD back to control levels ( Figure 9L) . These antinociceptive and analgesic effects are driven by activation of GC-C on colonic epithelial cells and the corresponding release of cGMP (4, 6, 8) . We show that linaclotide itself does not inhibit the excitability of colonic nociceptors, whereas its downstream effector cGMP causes dose-dependent inhibition of action potential firing, particularly in CVH states. We also show conclusively for the first time to our knowledge that cGMP acts on a membrane target that is accessed from an extracellular site to inhibit nociceptors. The precise molecular target that cGMP acts on extracellularly remains elusive but is the subject of continued investigation. We also observed that human DRG neurons, with a pathological phenotype following culture in inflammatory mediators, have an increased responsiveness to cGMP. Taken together, these findings demonstrate how chronic daily linaclotide treatment reduces chronic colonic hypersensitivity and chronic abdominal pain in a preclinical model of IBS. This may explain why long-term clinical use of linaclotide results in more IBS-C patients reporting abdominal pain relief over time (4, 5) , particularly if their underlying neuroplasticity is more entrenched following years of symptoms.
Recently, there has been an increased appreciation that IBS patients also suffer from a wide-range of extraintestinal comorbidities, including OAB and IC-PBS (13) . Although these symptoms contribute to the poor quality of life experienced by IBS patients, the underlying etiology of these comorbidities has been unclear. Here, we show that colitis-induced chronic colonic afferent hypersensitivity subsequently results in chronic bladder afferent hypersensitivity to mechanical and chemical stimuli. This leads to chronic hyperexcitability of bladder-innervating DRG neurons and, ultimately, chronic dysfunction of bladder voiding ( Figure 9K ). These chronic changes in bladder function are not due to colitis-induced inflammation of the bladder, nor due to changes in the contractility of the bladder. We show that bladder dysfunction takes several weeks to develop and occurs following the resolution of colitis and following the development of colonic hypersensitivity, which commonly presents 3-7 days after induction of colitis (20, 30) . Accordingly, these findings provide, for the first time to our knowledge, a mechanistic basis as to why IBS patients may also suffer from concurrent OAB/IC-PBS, particularly without a prior bladder infection or insult.
Our dual-retrograde tracing studies from the colon and bladder identified a small population of colon-innervating DRG neurons that also innervate the bladder (~15%), called dichotomizing afferents. As previously reported, these afferents have a single soma in the DRG but bifurcating axons that project to either the colon or bladder, respectively (14) (15) (16) . Accordingly, dichotomizing afferents have been proposed as a mechanism for viscero-visceral crosstalk and the basis of cross-organ sensitization (15, 16, 31, 32) . These dichotomizing afferents likely contribute directly to the cross-organ sensitization observed from the colon to the bladder in the current study, as they provide a clear mechanism by which sensitization of colonic afferents results in sensitization of bladder afferents. However, as they represent only approximately 15% of colon-innervating afferents, they are colonic mucosa of GC-C (gucy2c +/+ ) wild-type, but not gucy2c-null (gucy2c -/-) mutant mice. GC-C expression is absent in bladder samples from both gucy2c +/+ and gucy2c -/mice. Results were repeated in N = 3 mice/group. Scale bars: 200 μm (top); 50 μm (middle); 25 μm (bottom). (E) Quantitative RT-PCR confirming expression of gucy2c in primary colonic epithelium and absence in primary bladder urothelium. In comparison, trpv4 is highly expressed in bladder urothelium (N = 4-6 mice/group). (F) Ex vivo bladder afferent mechanosensitivity to ramp distension is increased in CVH (N = 7) compared with control (N = 6) mice. Bladder afferent responses from control or CVH mice are unaltered following ex vivo intravesical infusion of linaclotide (1,000 nM), showing linaclotide does not directly inhibit bladder afferents. (G) Action potential firing and intravesical pressure from control mice during bladder distension (0-30 mmHg) with intravesical saline and linaclotide (1,000 nM). Data represent mean ± SEM. P values are based on 1-way ANOVA (A and B) or 2-way ANOVA (F) with Bonferroni post hoc tests. unlikely to represent the entire mechanistic story of how transient colitis induces persistent bladder hypersensitivity. This is particularly apparent from our bladder ex vivo and patch-clamp recordings, whereby the vast majority of bladder-innervating afferents/neurons from CVH mice display hypersensitivity or hyperexcitability.
Interestingly, our retrograde tracing studies identified that the cell soma of distinct colon-and bladder-innervating afferents lie in close proximity to one another within the DRG. This is an important finding, as recent studies have shown that coupled activation of DRG neurons contributes to chronic pain (33) . In such a scenario, and following inflammation or nerve injury, adjacent neurons within the DRG activate together, and this is mediated by an injury-induced upregulation of gap junctions in the glial cells surrounding DRG neurons (33) . Interestingly, such interactions rarely occur in naive animals (33) . Such a mechanism provides a second plausible explanation whereby hypersensitive colon-innervating DRG neurons can subsequently sensitize bladder-innervating DRG neurons.
A third potential site of interaction is within the dorsal horn of the spinal cord. In the current study, we show that the central terminals of colon-innervating and bladder-innervating afferents are located in close proximity to one another within the spinal cord, thus projecting into shared dorsal horn circuits. In CVH mice, we observed an increased density and distribution of the central terminals of colonic afferents within the dorsal horn and activation of a different population of dorsal horn neurons in response to noxious CRD. Interestingly, a greater number of dorsal horn neurons activated in response to noxious CRD were immunoreactive for GABA, traditionally thought to identify inhibitory interneurons (22) . These findings potentially suggest that inhibition of inhibitory pathways may contribute to the neuroplasticity underling cross-organ sensitization between the colon and bladder. Therefore, colitis-induced enhancement of activation of spinal cord circuits could alter the spinal cord processing of bladder afferent input and therefore the sensory input then relayed into central micturition control regions. Such colitis-evoked changes could occur via the activation of spinal microglia, which are driving forces for maintaining pathological pain and for visceral and somatic sensitization following peripheral inflammation (34, 35) . Activated microglia release neuroexcitatory substances, proinflammatory cytokines, and growth factors, potentiating ectopic activation of dorsal horn neurons and neurite sprouting. Accordingly, the precise mechanisms by which sensitization of colonic afferent pathways results in persistent bladder afferent dysfunction is the subject of ongoing investigation.
Having established that chronic bladder dysfunction occurs in CVH states, we determined, in the first study of its kind to our knowledge, that daily linaclotide treatment is able to normalize bladder-voiding patterns and attenuate neuronal and mechanical bladder hypersensitivity of mice with CVH ( Figure 9L ). This also includes normalization of enhanced responses to TRPV1, P2X 3 , and muscarinic receptor agonists in CVH states, targets that are known to be essential for normal bladder function (36) (37) (38) . We observed that it takes 2 weeks of linaclotide treatment for the inhibitory actions on bladder afferents to become clearly evident. Linaclotide has a low oral bioavailability and remains localized to the colon (7, 8) . We also showed that GC-C is not expressed by bladder urothelial cells and that application of linaclotide into the lumen of the bladder does not influence mechanosensation or muscle compliance. Taken together, these findings indicate that normalization of bladder function by daily linaclotide treatment occurs via an indirect inhibition of bladder afferent signaling. We hypothesize that this could occur via (a) reduced nociceptive signaling from the colon, resulting in reduced neuronal firing of dichotomizing bladder afferents; or (b) via decreased coupled activation of colon-only and bladder-only innervating neurons within the DRG; or, finally, (c) linaclotide-induced reversal of neuroplasticity within the dorsal horn, restoring the circuitry for normal bladder function.
Overall, we have identified that both chronic abdominal pain and chronic bladder dysfunction occur in CVH states following the resolution of colitis. Our findings shed light on the mechanisms of cross-organ sensitization and provide the tantalizing prospect of treating multiple syndromes concurrently, while avoiding the debilitating side effects of current opioid-based pain treatments. Our findings may also have relevance beyond patients with IBS, as 30% of patients primarily defined as having OAB or IC-PBS exhibit symptoms of IBS among their most common comorbidities (11) . Linaclotide is FDA approved, well tolerated by patients, with few side effects, and may therefore provide a safe alternative treatment for these patients. Consequently, our findings identify mechanisms that may be taken advantage of in the future for the treatment of comorbid pelvic pain symptoms.
Methods
For extensive and details descriptions of the methodology used, please see the Supplemental Methods.
Animals and ethics. Male C57BL/6J mice aged 13-17 weeks were used for adult studies. Some experiments also utilized male mice lacking GC-C (gucy2c -/-, in-house breeding colony at SAHMRI), which were generated as described previously (39) . For FRET studies, R26-CAG-mcGi500 mice, which contain the sensor cGi500 under control of the ubiquitous CAG promoter, were used. R26-CAG-mcGi500 mice were generated as described previously (27) .
Mouse model of CVH. Mice were administered intracolonic TNBS and developed colitis (4, (18) (19) (20) (21) , with significant increases in MPO activity (Supplemental Figure 1) . While colonic inflammation spontaneously healed over a 7-day period (Supplemental Figure 1) , these mice subsequently developed chronic colonic afferent hypersensitivity in the postinflammatory state (4, (18) (19) (20) (21) .
Study design. Mice were randomly assigned to either (a) control or (b) CVH cohorts and then randomly assigned to 1 of 3 groups: those that received (a) no gavage, or (b) once daily 100-μl oral gavage of linaclotide (3 μg/kg/d) for 14 days, or (c) vehicle (water) once daily 100-μl oral gavage for 14 days. Daily oral administration began from 14 days after TNBS administration (or time/day matched for control animals) until 28 days after TNBS administration.
In vivo VMR to CRD. We assessed in vivo visceral sensitivity to CRD (the distension pressures 20, 40, 60, and 80 mmHg were used for these studies, each 20-second duration, applied at 4-minute intervals) using abdominal electromyography in fully awake animals. Colonic compliance was assessed by applying graded volumes (40-200 μl, 20-second duration) (40) (41) (42) .
Ex vivo single-fiber colonic nociceptor recordings. Ex vivo single-fiber colonic nociceptor recordings were made from control, CVH, or GC-C null (gucy2c -/-) mice using standard protocols (4, 18, 19, 21, 41) .
Visualization of pERK-activated neurons within the dorsal horn of the spinal cord following noxious CRD. 80 mmHg CRD was performed (10 seconds on, 5 second deflation, repeated 5 times). After anesthetic overdose, mice were fixed by transcardial perfusion, the spinal cord removed and cryoprotected. Frozen sections were cut and incubated with monoclonal-rabbit anti-phosphorylated-MAP-kinase-ERK-1/2 (pERK) (Cell Signaling Technology, 4370) visualized with Alexa Fluor 488 (ThermoFisher Scientific, A-21441) (4, 23) .
Retrograde tracing to label the cell bodies or central terminals of colon or bladder afferents. Cholera toxin subunit-B conjugated to Alexa Fluor 555 (CTB-555) was injected at 3 sites subserosally within the distal colon, while CTB-488 was injected into 3 sites into the bladder. Animals were left to recover for 4 days to identify cell bodies within the DRG or for 7 days to identify central terminals within the spinal cord (18, 23, 41) .
Patch-clamp recordings of colon-or bladder-innervating DRG neurons. Whole-cell patch-clamp recordings in current clamp mode were made from retrogradely traced colon-or bladder-innervating DRG neurons. 10 pA-depolarizing pulses of 500-millisecond duration were applied to determine rheobase (current required to fire an action potential) (18, 21) .
Human DRG neuron patch-clamp recordings. Human DRG neurons were acquired from organ donors with ethical consent, and whole-cell patch-clamp recordings were performed in current-clamp mode to determine rheobase (18) .
FRET-based cGMP imaging in DRG neurons. DRG neurons were isolated from R26-CAG-mcGi500(L1) embryos that express a membrane-targeted version of the FRET-based cGMP sensor cGi500 under control of the ubiquitous CAG promoter. FRET/cGMP imaging was performed 24 hours after plating DRG neurons (27) .
Bladder-voiding pattern analysis. Mice were individually housed in cages lined with filter paper for 3 hours. Filter paper was collected immediately prior to intracolonic TNBS administration and at days 7, 14, 21, and 28 after TNBS administration or the same time point for control mice. Filter paper was imaged using a Bio-Rad ultraviolet transilluminator and digitized into binary images using ImageJ (NIH).
Ex vivo electrophysiology for bladder afferent recordings and contractility studies. Whole pelvic nerve recordings were conducted in response to ramp distension (30 μl/min to 30 mmHg) (37, 43, 44) . Studies
